GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)

Episode 220

0:00-28:25

Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment. In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants. 02:24 Meet Paul Little 05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound 10:29 How ATR-258 tunes beta-2 signalling to mimic exercise 16:11 Avoiding the cardiovascular side effects of older beta-2 agonists 19:03 What the new muscle power and body composition data mean 22:03 Phase 2 options, oral advantages and the path to partnering Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Publisher

Beyond Biotech - the podcast from Labiotech

Published

October 23, 2026

Duration

28 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#muscleloss #battleground #obesitytreatment

The Nile